SMS Pharmaceuticals reports Q1 FY25 consolidated PAT at Rs. 16.48 Cr

SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024

Aarti Drugs posts Q1 FY25 PAT lower at Rs. 33.3 Cr

Briefs: Indoco Remedies and Alembic Pharmaceuticals

Indoco Remedies is addressing the observations comprehensively and will respond to the USFDA within the stipulated timeframe

Emcure Pharmaceuticals signs PPA with Sunsure Energy for solar power

The partnership will significantly advance their sustainability initiatives by meeting around 67% of their power requirements for these plants

European Commission approves Pfizer’s Durveqtix gene therapy for adults with hemophilia B

A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)

Cupid widens e-Commerce presence on leading Indian platforms

This strategic move aims to make Cupid's high-quality products more accessible to consumers nationwide

Industry hails Union Budget 2024-25

The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable

DGHS, Health Ministry, along with experts reviews the Chandipura virus and AES cases in states

Multidisciplinary central team deployed to assist Gujarat with epidemiological, environmental, and laboratory investigations of AES cases

Rusan Pharma’s API plant in Ankleshwar receives USFDA GMP approval

Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well

Lupin divests US commercial women's health specialty business to Evofem

Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones